It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
A long-held tenet in inositol-lipid signaling is that cleavage of membrane phosphoinositides by phospholipase Cβ (PLCβ) isozymes to increase cytosolic Ca2+ in living cells is exclusive to Gq- and Gi-sensitive G protein-coupled receptors (GPCRs). Here we extend this central tenet and show that Gs-GPCRs also partake in inositol-lipid signaling and thereby increase cytosolic Ca2+. By combining CRISPR/Cas9 genome editing to delete Gαs, the adenylyl cyclase isoforms 3 and 6, or the PLCβ1-4 isozymes, with pharmacological and genetic inhibition of Gq and G11, we pin down Gs-derived Gβγ as driver of a PLCβ2/3-mediated cytosolic Ca2+ release module. This module does not require but crosstalks with Gαs-dependent cAMP, demands Gαq to release PLCβ3 autoinhibition, but becomes Gq-independent with mutational disruption of the PLCβ3 autoinhibited state. Our findings uncover the key steps of a previously unappreciated mechanism utilized by mammalian cells to finetune their calcium signaling regulation through Gs-GPCRs.
Gs heterotrimers are considered to be poor providers of free Gβγ subunits. Here, the authors show that—despite this—Gs-derived Gβγ dimers are active transducers of GPCR-initiated Ca2+ signals involving phosphoinositide-based signaling routes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Jürgenliemke, Lars 3
; Grätz, Lukas 4
; Schihada, Hannes 5 ; Frechen, Fabian 6
; Alenfelder, Judith 2
; Pfeil, Cy 7 ; Ohse, Paul Georg 2 ; Hiratsuka, Suzune 8 ; Kawakami, Kouki 9
; Schmacke, Luna C. 5 ; Heycke, Nina 2 ; Inoue, Asuka 10
; König, Gabriele 11 ; Pfeifer, Alexander 12
; Wachten, Dagmar 6
; Schulte, Gunnar 4
; Steinmetzer, Torsten 5 ; Watts, Val J. 13 ; Gomeza, Jesús 2
; Simon, Katharina 14 ; Kostenis, Evi 2
1 University of Bonn, Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300); University of Bonn, Research Training Group 1873, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300)
2 University of Bonn, Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300)
3 University of Bonn, Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300); University of Bonn, Research Training Group 2873, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300)
4 Karolinska Institutet, Department of Physiology and Pharmacology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
5 Philipps-University Marburg, Department of Pharmaceutical Chemistry, Marburg, Germany (GRID:grid.10253.35) (ISNI:0000 0004 1936 9756)
6 University of Bonn, Institute of Innate Immunity, Medical Faculty, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300)
7 University of Bonn, Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300); University of Bonn, Research Training Group 1873, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300); Vrije Universiteit Amsterdam, Amsterdam Institute for Molecular and Life Sciences (AIMMS), Division of Medicinal Chemistry, Faculty of Science, Amsterdam, Netherlands (GRID:grid.12380.38) (ISNI:0000 0004 1754 9227)
8 Tohoku University, Graduate School of Pharmaceutical Sciences, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
9 Tohoku University, Graduate School of Pharmaceutical Sciences, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); The University of Tokyo, Komaba Institute for Science, Meguro, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2169 1048)
10 Tohoku University, Graduate School of Pharmaceutical Sciences, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Kyoto University, Graduate School of Pharmaceutical Sciences, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)
11 University of Bonn, Institute for Pharmaceutical Biology, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300)
12 University of Bonn, Institute of Pharmacology and Toxicology, University Hospital, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300)
13 Purdue University, Department of Medicinal Chemistry and Molecular Pharmacology, Purdue Institute of Drug Discovery, West Lafayette, USA (GRID:grid.169077.e) (ISNI:0000 0004 1937 2197)
14 University of Bonn, Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300); University of Padova, Department of Pharmaceutical and Pharmacological Sciences, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)




